Abstract
In a comparative double-blind trial involving 263 postmenopausal women with advanced breast cancer treated with tamoxifen, the mean objective tumour response rate and duration was 32% and 15 months respectively. No significant difference was found in clinical response and adverse effects between those randomised to 10 mg and those to 20 mg twice daily. Although the mean serum concentration of tamoxifen in the 20 mg bd group was significantly higher no correlation between serum level and clinical benefit was demonstrated.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Additional information
"Nolvadex" is a Trade Mark, the property of Imperial Chemical Industries PLC.
Rights and permissions
About this article
Cite this article
Bratherton, D., Brown, C., Buchanan, R. et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50, 199–205 (1984). https://doi.org/10.1038/bjc.1984.163
Issue Date:
DOI: https://doi.org/10.1038/bjc.1984.163
This article is cited by
-
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer
Clinical Pharmacokinetics (2022)
-
Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
Clinical Pharmacokinetics (2015)
-
Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
Breast Cancer Research and Treatment (2014)
-
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
Breast Cancer Research and Treatment (2012)
-
CYP2D6 and tamoxifen: DNA matters in breast cancer
Nature Reviews Cancer (2009)